Effective suppression of breast tumor growth by an anti-EGFR/ErbB2 bispecific antibody

Cancer Letters

Volumn 325, Issue 2, 2012, Pages 214-219

  Wang, Shuhui ^a   Chen, Changchun ^a   Meng, Yanchun ^b   Hu, Shi ^b   Zheng, Lei ^b   Song, Jinjing ^b   Zhang, Dapeng ^b,c   Li, Bohua ^b,c,d   Guo, Yajun ^a,b,c,d  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c National Engineering Research Center for Antibody Medicine   (China)

^d CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Bispecific; Breast cancer; EGFR; ErbB2; Monoclonal antibody

Indexed keywords

BISPECIFIC ANTIBODY; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TC BISPECIFIC ANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY ENGINEERING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY AFFINITY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL DIVISION; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865642389     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.07.007     Document Type: Article

References (23)

1. Spector N.L., Blackwell K.L. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 2009, 27:5838-5847.
2. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
3. Yu D., Hung M.C. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000, 19:6115-6121.
4. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney D.W., Leahy D.J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003, 421:756-760.
5. Hudis C.A. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 2007, 357:39-51.
6. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., Stewart S.J., Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20:719-726.
7. Valabrega G., Montemurro F., Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann. Oncol. 2007, 18:977-984.
8. Junttila T.T., Akita R.W., Parsons K., Fields C., Lewis Phillips G.D., Friedman L.S., Sampath D., Sliwkowski M.X. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009, 15:429-440.
9. Gajria D., Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev. Anticancer Ther. 2011, 11:263-275.
10. Nagata Y., Lan K.H., Zhou X., Tan M., Esteva F.J., Sahin A.A., Klos K.S., Li P., Monia B.P., Nguyen N.T., Hortobagyi G.N., Hung M.C., Yu D. PTEN activation contributes to tumor inhibition by trastuzumab and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
11. Martinelli E., De Palma R., Orditura M., De Vita F., Ciardiello F. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin. Exp. Immunol. 2009, 158:1-9.
12. Klijn J.G., Berns P.M., Schmitz P.I., Foekens J.A. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr. Rev. 1992, 13:3-17.
13. Wu C., Ying H., Grinnell C., Bryant S., Miller R., Clabbers A., Bose S., McCarthy D., Zhu R.R., Santora L., Davis-Taber R., Kunes Y., Fung E., Schwartz A., Sakorafas P., Gu J., Tarcsa E., Murtaza A., Ghayur T. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat. Biotechnol. 2007, 25:1290-1297.
14. Carter P., Presta L., Gorman C.M., Ridgway J.B., Henner D., Wong W.L., Rowland A.M., Kotts C., Carver M.E., Shepard H.M. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA 1992, 89:4285-4289.
15. Goldstein N.I., Prewett M., Zuklys K., Rockwell P., Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1995, 1:1311-1318.
16. Li B., Shi S., Qian W., Zhao L., Zhang D., Hou S., Zheng L., Dai J., Zhao J., Wang H., Guo Y. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res. 2008, 68:2400-2408.
17. Franklin M.C., Carey K.D., Vajdos F.F., Leahy D.J., de Vos A.M., Sliwkowski M.X. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004, 5:317-328.
18. Li B., Zhao L., Wang C., Guo H., Wu L., Zhang X., Qian W., Wang H., Guo Y. The protein-protein interface evolution acts in a similar way to antibody affinity maturation. J. Biol. Chem. 2010, 285:3865-3871.
19. Lee-Hoeflich S.T., Crocker L., Yao E., Pham T., Munroe X., Hoeflich K.P., Sliwkowski M.X., Stern H.M. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008, 68:5878-5887.
20. Carnahan J., Wang P., Kendall R., Chen C., Hu S., Boone T., Juan T., Talvenheimo J., Montestruque S., Sun J., Elliott G., Thomas J., Ferbas J., Kern B., Briddell R., Leonard J.P., Cesano A. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin. Cancer Res. Sep 19 2003, 3982S-3990S.
21. Shih L.B., Lu H.H., Xuan H., Goldenberg D.M. Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2. Int. J. Cancer 1994, 56:538-545.
22. Glennie M.J., French R.R., Cragg M.S., Taylor R.P. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 2007, 44:3823-3837.
23. Qu Z., Goldenberg D.M., Cardillo T.M., Shi V., Hansen H.J., Chang C.H. Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. Blood 2008, 111:2211-2219.